Group items tagged

9th Annual Eating Recovery Foundation Conference is organized by Eating Recovery Foundation and would be held during Aug 04 - 05, 2017 at Denver Marriott City Center, Denver, Colorado, United States of America. This CME Conference has been approved with a maximum of 14.5 CME Credits. Overaraching topics of discussion include: * Competency in the treatment of speciality patient populations * Commitment to collaboration within multidisciplinary treatment teams and across the continuum of care * Meeting unique treatment needs and improving treatment outcomes through innovation * Compassionate care for client and self Conference Objectives are : * Identify innovative treatment approaches to improve prevention, detection, treatment, and patient outcomes for eating and related disorders * Discuss recent advances in research, clinical pratices, and tools appropriate for ranging levels of acuity on the behavioral healtcare continuum * Employ creative and effective strategies to support the individual, engage the family and leverage the support system in treatment and recovery

For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according to a study published online Oct. 11 in the New England Journal of Medicine. Edward Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues conducted a multicenter trial to examine the efficacy and safety of combination treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults with HCV infection and compensated liver disease with severe renal impairment, dependence on dialysis, or both. Participants had stage 4 or 5 chronic kidney disease. One hundred four patients were enrolled in the trial. The researchers found that the sustained virologic response rate was 98 percent. During treatment, none of the patients had virologic failure, and none had a virologic relapse after the end of treatment. Pruritus, fatigue, and nausea were reported in at least 10 percent of the patients. Twenty-four percent of the patients reported serious adverse events. Because of adverse events, four patients discontinued the trial treatment prematurely; three of these had sustained virologic response

Torticollis and Plagiocephaly: Assessment and Treatment of Infants and Children is organized by Texas Children's Hospital and will be held during Mar 16 - 18, 2018, Houston, Texas, USA. The target audience for this medical event is Physical, Occupational & Speech Therapists; Nurses, including NICU, Nurse Practitioners, Orthotists, Physician Assistants, and Physicians. This CME Conference has been approved for a maximum of 13.5 contact hours or 1.35 CEU's Credits. Course Description: This dynamic evolving course will concentrate on progressive, effective treatment schemes for infants and young children with a diagnosis of torticollis with or without plagiocephaly, including challenging cases. The course is designed to provide therapists with current research and recommendations pertaining to the implications of torticollis, sleep posture and increased use of positional devices on infant postural and motor development. Current evidence-based clinical pathways and guidelines for management of torticollis and infant head shape, including Clinical Practice Guidelines from APTA - Section on Pediatrics, will be discussed and incorporated. Red flags for related early infancy and preschool diagnoses will be appraised. Current functional, clinically oriented evaluation and evidence based treatment strategies for infants and young children that can be integrated into routines and play will be provided. Diagnostic procedures and surgical intervention will be reviewed. Recommendations for follow-up and secondary specialist consultations will be presented. Emphasis on home exercise programs and effective strategies to team with parents will be explored.

Immediate access to opioid agonist treatment (OAT) for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care, according to a study published online Nov. 21 in the Annals of Internal Medicine. Emanuel Krebs, from St. Paul's Hospital in Vancouver, Canada, and colleagues sought to determine the cost-effectiveness of OAT versus observed standard of care for patients presenting with opioid use disorder. Population-level administrative databases capturing treatment and criminal justice records for California were linked (2006 to 2010). Immediate access to OAT for all treatment recipients was found by the researchers to cost less (by $78,257), with patients accumulating more quality-adjusted life-years (by 0.42) versus the observed standard of care. Imagining a hypothetical scenario where all Californians starting treatment of opioid use disorder in 2014 had immediate access to OAT, the team found that total lifetime savings for this cohort could be as high as $3.8 billion.

Management of type 2 diabetes should include shared decision making, and patients should be offered individualized diabetes self-management education and glycemic management plans, according to a summary of a clinical practice guideline published online Oct. 23 in the Annals of Internal Medicine. Paul R. Conlin, M.D., from the VA Boston Healthcare System in West Roxbury, Massachusetts, and colleagues convened a joint U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) Evidence-Based Practice Work Group to develop a guideline for management of type 2 diabetes mellitus. The authors provided updates on management within seven areas: patient-centered care and shared decision making, glycemic biomarkers, target ranges of hemoglobin A1c (HbA1c), individualized treatment plans, pharmacologic treatment in the outpatient setting, glucose targets for critically ill patients, and treatment for patients in the hospital. Patients should be offered individualized diabetes self-management education, as well as individualized glycemic management plans and target ranges for HbA1c. "In summary, the VA/DoD CPG [clinical practice guideline] attempts to convey to clinicians, policymakers, and patients the rationale for personalizing treatment on the basis of results from major trials, limitations of the HbA1c test, and evaluation of patient risk for adverse drug events. Conveying complex information in an understandable manner to individual patients and families through a formal process of shared decision making is thus foundational to setting and revising goals that are meaningful, safe, and achievable in everyday clinical practice," the authors write.

For patients with unruptured intracranial aneurysms (UIAs) that are 3 mm or smaller, no preventive treatment or imaging follow-up is the most effective management strategy, according to a study published online Nov. 20 in JAMA Neurology. Ajay Malhotra, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues used inputs from the medical literature to conduct a decision-analytic model-based comparative effectiveness analysis. Five management strategies were assessed: annual magnetic resonance angiography (MRA) screening, biennial MRA screening, MRA screening every five years, aneurysm coiling and follow-up, and no treatment or preventive follow-up. In an analysis of 10,000 iterations simulating adult patients, the researchers found that the highest health benefit was seen for the management strategy of no treatment or preventive follow-up (mean quality-adjusted life-years, 19.40). MRA every five years was the best of the management strategies that incorporate follow-up imaging, with the next highest effectiveness (mean quality-adjusted life-years, 18.05). When the annual growth rate and risk of rupture of growing aneurysms are varied, no routine follow-up remains the optimal strategy. No follow-up is the optimal strategy when the annual risk of rupture of nongrowing UIAs is less than 1.7 percent; coiling should be performed directly if the annual risk of rupture is >1.7 percent.

Diabetes Intensive Training is organized by Mayo clinic and would be held during Jul 10 - Sep 29, 2017. The target audience for this medical event basically for Endocrinology, Metabolism and Diabetes, The CME conference has been approved with maximum of 32.00 AMA PRA Category 1 Credit. he Diabetes Intensive Training online course is a comprehensive web based graduate credit level professional enhancement course geared toward practicing professionals. Diabetes Intensive Training is an online self-paced 12 week course through Blackboard Learn. The course is offered on a quarterly basis. The curriculum includes a pretest, 16 modules for study, a post-test requiring an 80% passing score for continuing education credit, and a required evaluation of the course at completion. Currently the curriculum is offered to physicians, physician assistants, advanced nurse practitioners, registered nurses and pharmacists with a current license without restrictions. Target audience: This course is designed for Primary care providers - Family Medicine and General Internal Medicine MDs, Pharmacists, Dietitians, NPs, RNs and APRNs. Learning objectives: Upon conclusion of this program, participants should be able to: * Integrate the principles of theory and research of nursing and medicine into comprehensive health care plan for patients with diabetes including prevention, promotion and treatment * Demonstrate knowledge of evidence based and clinical guidelines in treatment of diabetes inpatient and outpatient management. * Develop and acquire skills for self- directed lifelong learning and staying current in diabetes management (prevention, promotion and treatment).

Vascular Interventional Advances Annual Conference (VIVA) is organized by Vascular Interventional Advances (VIVA) and would be held during Nov 11 - 15, 2017 at Wynn Las Vegas, Las Vegas, Nevada, United States of America. TARGET AUDIENCE : The target audience for this CME activity is physicians who specialize in, among other areas, interventional cardiology, interventional radiology, vascular medicine, vascular surgery, cardiothoracic surgery, neurosurgery, podiatry and neuroradiology, as well as fellows, and allied health professionals (including nurses, vascular clinic staff, endovascular operating room staff, catheterization laboratory and angiography suite staff, nurse practitioners, vascular technologists, and physicians assistants). LEARNING OBJECTIVES : At the conclusion of the course, the targeted learners should be able: * Understand the current indications, risks, complications, and outcome of medical, interventional, and surgical therapies for the treatment of peripheral arterial and venous diseases. * Incorporate advanced medical, endovascular, and surgical techniques and approaches into their own practices to improve the care and outcomes of patients. * Implement high quality guidelines based programs to improve the early identification and care of patients with non- cardiac vascular conditions. * Increase knowledge in critical decision-making and the comprehensive spectrum of care for patients with stroke and intracranial and extracranial carotid artery disease. * Improve the delivery of balanced and scientifically valid vascular care in accordance with expert opinion and practice. * Utilize strategies learned from the meeting including endovascular technologies, open surgical techniques, and hybrid approaches, for the treatment of patients with aortic diseases. * To gain and employ decision making and procedural strategies and techniques in patients with aortic and visceral aneurysms, dissections, deep venous thrombosis, venous insufficiency and pu

Water - Based Interventions for the Pediatric Therapies is organized by Texas Children's Hospital and will be held during Mar 03 - 04, 2018 at Blue Lagune Therapy - Aquatic & Land Physical Therapy, Katy, Texas, United States of America. This CME Conference has been approved for a maximum of 16 CCUs Credits. Course Description: This Course is designed to rapidly introduce pediatric therapists to motor, sensory and play-based interventions in water. Participants will create a series of aquatic therapeutic movements, tasks, or exercises designed to alleviate the most common problems associated with the pediatric population and then adapte these ideas to novel situations. Participants will briefly examine research which supports aquatic therapy for the child and explore contraindications, including prevailing precaution myths. Course Objectives : * Discriminate between aquatic precautions and contraindications specific to the pediatric client. Defend any choice, on a case-by-case basis, to label a condition as a precaution and not as a contraindication. * Explain why aquatic therapy may be the treatment of choice if (a) the patient has poor head or trunk righting/control, (b) the patient has spasticity, (c) the patient has difficulty with transitional movements; (d) the patient has poor sensory processing; (e) the patient has speech/language deficits; or (f) research supports its use. * Design a sample aquatic treatment session demonstrating 2 ways to divide labor between PT, OT and SLP. Compare and contrast 5 ways that the goals of 3 different disciplines should differ. Recommend 3 ways to co-treat in water and be reimbursed for the services provided. * Originate, integrate, and combine ideas into a plan to implement augmentative communication in the therapy pool setting. Incorporate low-tech augmentative communication methods during labs to improve communication. * Gather and organize the latest aquatic research to bolster the case for treatment and to aid in t

44th Annual Vascular and Endovascular Issues, Techniques, Horizons (VEITH) Symposium is organized by Cleveland Clinic and would be held during Nov 14 - 18, 2017 at New York Hilton Midtown, New York, United States of America. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Objectives : Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to: * Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease * Summarize the impact of data on therapeutic advances for stroke and carotid disease management * Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease * Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care * Summarize recent data on treatment advances for venous disease and explain their clinical implications * Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors

The cannabinoids in medical cannabis have anti-inflammatory effects, which are beneficial for reducing IBD symptoms, appetite loss, abdominal pain, diarrhea, etc. Cannabis treatment for gut problems is safe as compared to other available medical treatments. To access medical marijuana legally, you require a doctor's recommendations. And, medical marijuana card renewal is necessary after 12 months if you wish to continue using cannabis for medicinal benefits.

Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care. Tom F. Brouwer, M.D., from the University of Amsterdam, and colleagues assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from two randomized trials (ACCORD-BP [Action to Control Cardiovascular Risk in Diabetes Blood Pressure]and SPRINT [Systolic Blood Pressure Intervention Trial] studies; total of 14,094 patients). The researchers found that the mean baseline systolic blood pressure was 139.5 mm Hg for the cohort and just over one-third (33.6 percent) had type 2 diabetes. The hazard ratio for the primary composite end point of unstable angina, myocardial infarction, acute heart failure, stroke, and cardiovascular death was 0.82 (P = 0.0017). There was a nonsignificant interaction between intensive blood pressure lowering and type 2 diabetes (P = 0.13). While the 10-year cardiovascular risk was higher in patients with type 2 diabetes, there was no interaction between the risk and treatment effect (P = 0.84).

Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism. Melanie J. Davies, M.D., from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5,908 participants in five randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk. The researchers found that with liraglutide (3.0 mg), eight participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years). Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95 percent confidence interval, 0.17 to 1.08).

For young patients with type 1 diabetes, insulin pump therapy is associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and better glycemic control than insulin injection therapy, according to a study published online Oct. 10 in the Journal of the American Medical Association. Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study in 446 diabetes centers. They identified patients with type 1 diabetes who were younger than 20 years and had diabetes duration of more than one year. The researchers found that 14,119 patients used pump therapy and 16,460 used insulin injections. A total of 9,814 patients using pump therapy were matched with 9,814 using injection therapy. Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years). Lower levels of glycated hemoglobin were seen with pump versus injection therapy (8.04 versus 8.22 percent). Compared with injection therapy, pump therapy was associated with lower total daily insulin doses (0.84 versus 0.98 U/kg). No significant difference in body mass index was seen between the treatment regimens

Cannabis seems like a promising treatment option for people with arthritis. If it affects brain receptors and the immune system in the way that medical practitioners believe, it can prove to be extremely beneficial in treating arthritis.

As a cardiologist, your expertise includes the diagnosis, treatment and prevention of heart and blood vessel diseases. Patients of all ages may be sent to you, or perhaps you have chosen to specialize in an area like geriatric or pediatric cardiology. And even though you have completed an extensive amount of internal medicine and cardiology education to-date, on-going training requirements must still be fulfilled. We can help you find continuing medical education (CME) courses that are just as specialized as your skill set. Our database of cardiology medical conferences can help you find CME opportunities that meet your needs. In addition to general cardiovascular medicine events, we feature conferences dedicated to specific topics like heart rhythm, echocardiography, hypertension and more. Register for events hosted by leading hospitals in cardiology such as the Cleveland Clinic and the Mayo Clinic. Are you ready to attend your next cardiology conference? To get started, review our list of upcoming Fellows courses, annual updates, case reviews, forums and more. And for additional events, we recommend checking out our database of Interventional Cardiology and Vascular Disease conferences.

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 2, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

KT3: Clinical concept and advanced whole body application is organized by Texas Children's Hospital and will be held on Jan 26, 2018 at Texas Children's Hospital, Houston, Texas, USA. This CME Conference has been approved for a maximum of 8 CCUs or 8 contact hours. Course Description : The KT3 course combines the Kinesio Taping Method foundational concepts of KT1&KT2 with advanced clinical concepts. The course provides lab time for attendees to practice their skills on the new concepts through a variety of clinical applications. The KT3 course is designed to allow the Certified Kinesio Taping Instructor (CKTI) to cater specific clinical applications to address specific professions. Upon completion of this course and prerequisite KT1&KT2 seminar, attendees will be eligible to request and take the exam to become a Certified Kinesio Taping Practitioner (CKTP). Note: Students can request to take the exam but will not be eligible to receive a CKTP certificate until they graduate. Course Objectives are : * Review the basic concepts of the Kinesio Taping Method * Explain and apply advanced concepts of the Kinesio Taping Method * Review epidermis, dermis, and fascial anatomy as it is related to Kinesio Taping * Utilize and demonstrate application skills in guided laboratory sessions * Apply the Kinesio Taping Method to stimulate epidermis, dermis, and fascial response * Apply advanced clinical taping techniques for treatment of the spine, neurological conditions, and upper/lower extremity dysfunction

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 02, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.